Investors

Overview

Corporate Profile

Forward Pharma is a biotechnology company focused on the immunomodulatory compound dimethyl fumarate and derivatives, for applications as a pharmaceutical drug product to treat immune disorders such as multiple sclerosis and psoriasis.

Forward Pharma A/S was founded in 2005 and is headquartered in Copenhagen, Denmark, in the heart of Medicon Valley. Since 2007 we have also operated out of a subsidiary, Forward Pharma GmbH, in Leipzig, Germany, and since August 2014 out of a subsidiary in the United States, Forward Pharma USA, LLC.


Most Recent Presentation
Download Documentation JMP Securities Healthcare Conference

Stock Information
FWP (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Financial Status IndicatorC
Price$20.11
Change (%) Stock is Up 0.16 (0.80%)
Volume659
Data as of 09/23/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock chart for: FWP.OQ.  Currently trading at $20.11 with a 52 week high of $29.12 and a 52 week low of $11.22.

Recent NewsMore >>
DateTitle 
09/06/16Forward Pharma CFO to Participate in Three Investor Conferences in September
COPENHAGEN, Denmark, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel Sendek, the Company’s Chief Financial Officer, will participate in the following conferences: Wells Fargo Securities Healthcare Conference to be held at the Westin Boston Waterfront in Boston, Mas... 
Printer Friendly Version
09/01/16Forward Pharma Reports Second Quarter 2016 Financial and Operational Results
COPENHAGEN, Denmark, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward” or the “Company”), today reported financial results for the second quarter ended June 30, 2016.  Net loss for the second quarter ended June 30, 2016 was $15.1 million, or $0.32 per basic share versus a net loss of $17.7 million, or $0.38 per basic share for second quarter of 2015.  On a non-GAAP basis, after removing the effect of non-cash income and expense items, our second quarter net ... 
Printer Friendly Version
06/06/16Forward Pharma CFO to Participate in Two Investor Conferences in June
COPENHAGEN, Denmark, June 06, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (the “Company”), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel Sendek, the Company’s Chief Financial Officer, will participate in the following conferences: Jefferies Healthcare Conference to be held at the Grand Hyatt in New York, New York.  Mr. Sendek will p... 
Printer Friendly Version
06/02/16Forward Pharma Reports First Quarter 2016 Financial and Operational Results
COPENHAGEN, Denmark, June 02, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We” or “Forward” or the “Company”), today reported financial results for the first quarter ended March 31, 2016.  Net loss for the first quarter ended March 31, 2016 was $16.9 million, or $(0.36) per basic share versus net income of $6.0 million, or $0.13 per basic share for first quarter of 2015.  On a non-GAAP basis, after removing the effect of non-cash income and expense items, our first quarter net lo... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
11/06/16
through
11/08/16
Forward Pharma A/S at Credit Suisse Healthcare Conference
LocationScottsdale, AZ
12/07/16
through
12/08/16
Forward Pharma A/S at Citi Healthcare Conference
LocationNew York, NY
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Forward Pharma A/S posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources